Valuation: Myriad Genetics, Inc.

Market Cap 274M 237M 221M 203M 383M 26.09B 390M 2.6B 1.02B 13B 1.03B 1B 43.06B P/E 2026 *
-4.27x
P/E 2027 * -5.4x
Enterprise Value 274M 237M 221M 203M 383M 26.09B 390M 2.6B 1.02B 13B 1.03B 1B 43.06B EV / Sales 2026 *
0.33x
EV / Sales 2027 * 0.31x
Free-Float
95.08%
Yield 2026 *
-
Yield 2027 * -
1 day-46.74%
1 week-49.02%
1 month-49.91%
3 months-39.79%
6 months-49.11%
Current year-53.50%
1 week 2.81
Extreme 2.81
5.76
1 month 2.81
Extreme 2.81
6.43
Current year 2.81
Extreme 2.81
7.15
1 year 2.81
Extreme 2.81
8.59
3 years 2.81
Extreme 2.81
29.3
5 years 2.81
Extreme 2.81
36.95
10 years 2.81
Extreme 2.81
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer - 2026-05-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Date Insider Type Main position Quantity % Market Cap.
6/11/26 Free

Chief Executive Officer

3,542 0.0038%
3/22/26 Tax

Chief Operating Officer

2,055 0.0022%
3/1/26 Tax

Head of Human Resources

1,675 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-46.74%-49.02%-25.52%-87.20% 274M
+6.33%+9.95%+295.29%+315.15% 21.74B
-3.83%-1.14%-45.07%-29.17% 9.38B
-1.35%-4.94%+39.96%+15.20% 6.49B
-4.37%+2.16%+251.45%-24.94% 6B
-1.81%-0.93%-13.78%-15.42% 5.57B
-2.61%+0.97%-44.20% - 4.43B
+4.21%+7.67%-16.15%-29.58% 4.38B
+9.99%+1.30%+75.99%+91.71% 4.25B
-1.02%+5.24%-16.77%-40.86% 2.8B
Average -4.12%+0.91%+50.12%+21.65% 6.53B
Weighted average by Cap. +1.38%+3.38%+117.76%+107.79%

Financials

2026 *2027 *
Net sales 826M 716M 667M 612M 1.16B 78.75B 1.18B 7.85B 3.08B 39.22B 3.1B 3.03B 130B 881M 764M 712M 654M 1.24B 84.07B 1.26B 8.38B 3.29B 41.87B 3.31B 3.24B 139B
Net income -62.71M -54.4M -50.63M -46.52M -87.9M -5.98B -89.31M -596M -234M -2.98B -235M -230M -9.87B -50.98M -44.22M -41.16M -37.82M -71.46M -4.86B -72.61M -485M -190M -2.42B -191M -187M -8.02B
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-07-31 US$2.860 -46.74% 15,162,792
26-07-30 US$5.370 +6.55% 2,156,224
26-07-29 US$5.040 -5.26% 1,475,512
26-07-28 US$5.320 -2.39% 1,164,945
26-07-27 US$5.450 -2.85% 1,172,182
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
2.860USD
Average target price
5.750USD
Spread / Average Target
+101.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock